Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer.

Mallick, U; Harmer, C; Yap, Beng K; Wadsley, J; Clarke, S; Moss, L; Nicol, A; Clark, P; Farnell, K; McCready, R; Smellie, J; Franklyn, J; John, R; Nutting, C; Newbold, K; Lemon, C; Gerrard, G; Abdel-Hamid, A; Hardman, J; Macias, E; Roques, T; Whitaker, S; Vijayan, R; Alvarez, P; Beare, S; Forsyth, S; Kadalayil, L; Hackshaw, A

Affiliation

Northern Centre for Cancer Care, Freeman Hospital, Level 4, Freeman Rd., Newcastle upon Tyne, NE7 7DN United Kingdom.

Issue Date

2012-05-03

Metadata

Show full item record

Abstract

It is not known whether low-dose radioiodine (1.1 GBq [30 mCi]) is as effective as high-dose radioiodine (3.7 GBq [100 mCi]) for treating patients with differentiated thyroid cancer or whether the effects of radioiodine (especially at a low dose) are influenced by using either recombinant human thyrotropin (thyrotropin alfa) or thyroid hormone withdrawal.

Citation

Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. 2012, 366 (18):1674-85 N Engl J Med

Journal

New England Journal of Medicine

URI

http://hdl.handle.net/10541/251871

DOI

10.1056/NEJMoa1109589

PubMed ID

22551128

Type

Article

Language

ISSN

1533-4406

Collections

All Christie Publications